No abstract available
Plain language summary
This study estimates public and private spending on genetically targeted treatments for Duchenne muscular dystrophy during years in which the drugs were marketed without completed confirmatory studies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Letter
MeSH terms
-
Humans
-
Molecular Targeted Therapy* / economics
-
Muscular Dystrophy, Duchenne* / drug therapy
-
Muscular Dystrophy, Duchenne* / economics